GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (STU:24O0) » Definitions » Debt-to-EBITDA

Reshape Lifesciences (STU:24O0) Debt-to-EBITDA : -0.03 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Reshape Lifesciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.10 Mil. Reshape Lifesciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.12 Mil. Reshape Lifesciences's annualized EBITDA for the quarter that ended in Mar. 2024 was €-8.11 Mil. Reshape Lifesciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Reshape Lifesciences's Debt-to-EBITDA or its related term are showing as below:

STU:24O0' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.73   Med: -0.02   Max: -0.01
Current: -0.02

During the past 13 years, the highest Debt-to-EBITDA Ratio of Reshape Lifesciences was -0.01. The lowest was -0.73. And the median was -0.02.

STU:24O0's Debt-to-EBITDA is ranked worse than
100% of 439 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs STU:24O0: -0.02

Reshape Lifesciences Debt-to-EBITDA Historical Data

The historical data trend for Reshape Lifesciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Debt-to-EBITDA Chart

Reshape Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.73 -0.01 -0.01 -0.02

Reshape Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.02 -0.02 -0.04 -0.03

Competitive Comparison of Reshape Lifesciences's Debt-to-EBITDA

For the Medical Devices subindustry, Reshape Lifesciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Debt-to-EBITDA falls into.



Reshape Lifesciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Reshape Lifesciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.102 + 0.138) / -13.283
=-0.02

Reshape Lifesciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.103 + 0.117) / -8.112
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Reshape Lifesciences  (STU:24O0) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Reshape Lifesciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences (STU:24O0) Business Description

Traded in Other Exchanges
Address
1001 Calle Amanecer, San Clemente, CA, USA, 92673
Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Reshape Lifesciences (STU:24O0) Headlines

No Headlines